Single-dose rituximab to prevent EBV after kidney transplant
Treatments studied
Part of Infections clinical trials.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older at the time of your transplant
- You received a kidney transplant (and also a kidney-pancreas transplant at the same time)
- You were EBV-negative before transplant (blood tests: EBV marker tests are negative in the 6 months before through transplant day)
- Your donor kidney was EBV-positive
- You can take part in study visits and follow the plan, and you are not in another drug treatment study
- If you could become pregnant: you have a negative pregnancy test and will use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
This study tests whether a medication called rituximab can help prevent a type of cancer (PTLD) that sometimes develops in transplant patients whose body is fighting a reactivated virus (EBV). You may qualify if you've had an organ transplant, have high levels of EBV in your blood, and haven't yet developed this cancer.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
Hear when a new Epstein-Barr Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.